Dr. Alok Khorana

Oncology
10201 Carnegie Avenue, 
Cleveland, OH 
On Staff At
Offers Telehealth
10201 Carnegie Avenue, 
Cleveland, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Alok Khorana is an Oncologist in Cleveland, Ohio. Dr. Khorana is rated as an Experienced provider by MediFind in the treatment of Morning Sickness. His top areas of expertise are Venous Thromboembolism (VTE), Pancreatic Cancer, Colorectal Cancer, Pancreatectomy, and Endoscopy.

His clinical research consists of co-authoring 263 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Residency
Millard Fillmore Gates Circle Hospital / Kaleida Health
Specialties
Oncology
Licenses
Internal Medicine in NY
Board Certifications
American Board Of Internal Medicine, 2002
Fellowships
University of Rochester Medical Center
Hospital Affiliations
Cleveland Clinic
Akron General Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Cleveland Clinic Main Campus
10201 Carnegie Avenue, Cleveland, OH 44106

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Dose Escalation and Cohort Expansion Study of DKN-01 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Carcinoma Primary to the Intra- or Extra-hepatic Biliary System or Gallbladder
A Dose Escalation and Cohort Expansion Study of DKN-01 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Carcinoma Primary to the Intra- or Extra-hepatic Biliary System or Gallbladder
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
Enrollment Status: Completed
Publish Date: January 22, 2025
Intervention Type: Drug, Other
Study Drugs: Tucatinib, Trastuzumab, Ramucirumab, Paclitaxel
Study Phase: Phase 2/Phase 3
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas
Enrollment Status: Completed
Publish Date: January 03, 2023
Intervention Type: Drug
Study Drugs: CPI 613, mFolfirinox, Folfirinox
Study Phase: Phase 3
A Randomized, Phase II Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients
A Randomized, Phase II Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients
Enrollment Status: Completed
Publish Date: July 08, 2021
Intervention Type: Drug
Study Drug: Enoxaparin
Study Phase: Phase 2
A Prospective, Multinational, Multi-Center, Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy, Safety and Tolerability of siG12D-LODER in Combination With Standard of Care Chemotherapy in the Treatment of Patients With Locally Advanced Pancreatic Cancer
A Prospective, Multinational, Multi-Center, Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy, Safety and Tolerability of siG12D-LODER in Combination With Standard of Care Chemotherapy in the Treatment of Patients With Locally Advanced Pancreatic Cancer
Enrollment Status: Unknown
Publish Date: July 02, 2021
Intervention Type: Drug
Study Drugs: siG12D-LODER, Gemcitabine+Nab-Paclitaxel, Folfirinox
Study Phase: Phase 2
View 5 Less Clinical Trials

263 Total Publications

Cabozantinib and thromboembolism in patients with cancer: a systematic review, meta-analysis and retrospective study.
Cabozantinib and thromboembolism in patients with cancer: a systematic review, meta-analysis and retrospective study.
Journal: Blood advances
Published: August 12, 2025
Similar Doctors
Experienced in Morning Sickness
Dr. Ameet P. Patel
Oncology | Hematology | Hematology Oncology
Experienced in Morning Sickness
Dr. Ameet P. Patel
Oncology | Hematology | Hematology Oncology

Cleveland Clinic

9500 Euclid Ave, 
Cleveland, OH 
 (0.3 miles away)
216-444-3046
Experience:
10+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ameet Patel is an Oncologist and a Hematologist in Cleveland, Ohio. Dr. Patel has been practicing medicine for over 10 years and is rated as an Advanced provider by MediFind in the treatment of Morning Sickness. His top areas of expertise are Febrile Neutropenia, Agranulocytosis, Chronic Familial Neutropenia, Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration. Dr. Patel is currently accepting new patients.

Experienced in Morning Sickness
Dr. Adarsh Vennepureddy
Hematology Oncology | Hematology | Oncology
Experienced in Morning Sickness
Dr. Adarsh Vennepureddy
Hematology Oncology | Hematology | Oncology

Cleveland Clinic

9500 Euclid Ave, 
Cleveland, OH 
 (0.3 miles away)
216-444-5433
Languages Spoken:
English, Hindi, Telugu
See accepted insurances
Accepting New Patients
Offers Telehealth

Adarsh Vennepureddy is a Hematologist Oncology specialist and a Hematologist in Cleveland, Ohio. Dr. Vennepureddy is rated as an Advanced provider by MediFind in the treatment of Morning Sickness. His top areas of expertise are Small Lymphocytic Lymphoma (SLL), Pulmonary Embolism, Thrombocytopenia, and Familial Pancreatic Cancer. Dr. Vennepureddy is currently accepting new patients.

Experienced in Morning Sickness
Dr. Allison Winter
Hematology Oncology | Hematology | Oncology
Experienced in Morning Sickness
Dr. Allison Winter
Hematology Oncology | Hematology | Oncology

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (0.3 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Allison Winter is a Hematologist Oncology specialist and a Hematologist in Cleveland, Ohio. Dr. Winter is rated as a Distinguished provider by MediFind in the treatment of Morning Sickness. Her top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Khorana's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 32 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile